Purinergic Mechanisms In Nervous System Function And Disease States

Michael F. Jarvis* and Michael Williams
Neurological and Urological Diseases Research D-4PM
Abbott Laboratories
Abbott Park IL 60064-3500
Phone: (847) 937-3919
Fax: (847) 937-9195
E-Mail: michael.f.jarvis@abbott.com


1)          Akbar GKM, Dasari VR, Webb TE, Ayyanathan K, Pillarisetti K, Sandhu AK, Athwal RS, Daniel JL, Ashby B, Barnard EA, Kunapuli SP Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells. J Biol Chem 1996; 271:18363-18367.

2)          Atkinson DE The energy charge of the adenylate pool as a regulatory parameter. Interaction with feedback modifers. Biochem. 1968; 7: 4030-4034.

3)          Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, Bitner RS, Pauly JL, Diaz A, Dickenson AH, Williams M. Broad spectrum, non-opioid analgesic activity by selective modulation of nicotinic acetylcholine receptors. Science 1998; 279: 77-81.

4)          Berne RM. Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow. Am. J. Physiol. 1963: 204: 317 - 322.

5)          Bianchi, B., Yu, H., Jarvis, M.F., Kowaluk, E.A., van Biesen, T. Radioligand binding assays using [35S]ATPgS or [35S]ADPbS are non-selective for ionotropic or metabotropic P2 receptor subtypes. Mol. Pharmacol. submitted.

6)          Brundege JM, Dunwiddie TV. Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv. Pharm., 1997, 39, 353-391.

7)          Bruns RF, Fergus JH. Allosteric enhancement of adenosine A1 receptor binding and function by 2 - amino - 3 - benzoyl - thiophenes. Mol. Pharmacol. 1990, 38, 939 - 949.

8)          Burnstock G. Purinoceptors: ontogeny and phylogeny. Drug Dev. Res. 1996, 39, 204 - 242.

9)          Burnstock G. A unifying purinergic hypothesis for the initiation of pain. Lancet 1996, 347, 1604 -1605.

10)       Burnstock G, Barnard EA ATP as a neurotransmitter. Ciba Found. Symp. 1996, 198, 260 - 265.

11)       Camaioni E, Boyer JL, Mohanram A, Harden TK, Jacobson K A Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. J Med Chem 1998; 41:183- 190.

12)       Carley D, Radulovacki M. Adenosine effects in sleep apnea. In: Purinergic Approaches in experimental Therapeutics. Eds. Jacobson KA. Jarvis M F, Wiley-Liss, New York, pp.515-526.

13)       Chessell IP Michel AD Humphrey PPA. Properties of the pore-forming P2X7 purinoceptor in mouse NTW8 microglial cells. Br. J. Pharmacol. 1997 121, 1429 - 1437.

14)       Chessell IP Michel AD Humphrey PPA. Effects of antagonists at the human recombinant P2X7 receptor. Br. J. Pharmacol. 1998 124, 1314 - 1320.

15)       Chow SC. Kass GEN Orrenius S. Purines and their role in apoptosis, Neuropharmacol. 1997 36: 1149 - 1156.

16)       Clifford EE. Martin KA, Dalal P, Thomas R. Dubyak, GR Stage specific expression of P2Y receptors, ecto-apyrase and ecto-5-nucleotidase in myeloid leukocytes. Am. J. Physiol. 1997, 273(Cell Physiol. 42) , C973 - C987.

17)       Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G Tissue distribution of the P2X7 receptor. Neuropharmacology 1997; 36:1277-1283.

18)       Communi D, Govaerts C, Parmentier M, Boeynaems JM Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 1997; 272:31969-31973.

19)       Conti JB, Belardinelli L, Utterback DB, Curtis AB Endogenous adenosine is an antiarrhymic agent. Circulation 1995; 15: 1761-1767.

20)       Cook SP, Vulchanova L, Hargreaves KM, Elde R, McCleskey EW Distinct ATP receptors on pain-sensing and stretch-sensing neurons. Nature 1997; 387:505-508.

21)       Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273:2024-2029.

22)       Di Virgilio F, Falzoni S, Mutini C, Sanz JM, Chiozzi P Purinergic P2X7 receptor: a pivotal role in inflammation and immunomodulation. Drug Dev. Res. 1998 45, in press.

23)       Dragunow M. ADO and epileptic seizures. In Phillis JW, ed. Adenosine and Adenine Nucleotides as Regulators of Cellular Function. Boca Raton, FL, CRC Press, 1991, 367 - 379.

24)       Driessen B., Reimann W. Selve N., Friderichs, E. Bultmann, R. Antinociceptive activity of intrathecally administered P2-purinoceptor antagonists in rats. Brain Res. 1994 666, 182 - 188.

25)       Drury AN, Szent - Gyorgi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian brain. J. Physiol. (Lond.) 1929, 68, 480 - 487.

26)       Dubyak GR. El Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Amer. J. Physiol. 1993, 265, C577 - C606.

27)       Dubyak GR, Clifford, EE, Humphreys BD, Kertsey SB Martin KA Expression of multiple ATP subtypes during the differentiation and inflammatory activation of myeloid leukocytes. Drug. Dev. Res. 1996, 39, 269 - 278.

28)       During MJ, Spencer DD Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol 1992; 32:618-624.

29)       Engler R Consequences of activation and adenosine-mediated inhibition of granulocytes during myocardial ischemia. Fed Proc 1987; 46:2407-2412.

30)       Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997; 20:482-487.

31)       Firestein G Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev. Res. 1996; 39: 371-376.

32)       Freedman JE Lin, T-J. (1996) ATP-sensitive potassium channels: diverse functions in the central nervous system. Neuroscientist , 2, 145 - 152.

33)       Fukunaga AF. Purines in anesthesia. In Purinergic Approaches in Experimental Therapeutics. Eds Jacobson KA, Jarvis MF, Wiley-Liss, New York, 1997, pp. 471 - 493.

34)       Gargett CE, Wiley JS The isoquinoline derivative KN-62 a potent antagonist of the P2Z- receptor of human lymphocytes. Br J Pharmacol 1997; 120:1483-1490.

35)       Geiger JD, Parkinson F, Kowaluk EA Regulators of endogenous adenosine levels as therapeutic agents. In: Purinergic Approaches in Experimental Therapeutics Jacobson KA, Jarvis MF, Wiley-Liss, Inc. New York, 1997, 55-84

36)       Harden TK, Boyer JL, Nicholas RA P2-purinergic receptors: subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 1995; 35:541-579.

37)       Housley GD.Extracellular nucleotide signalling in the inner ear. Mol. Neurobiol. 1998, 16, 21 - 48.

38)       Hoyle CH Pharmacological activity of adenine dinucleotides in the periphery: possible receptor classes and transmitter function. Gen Pharmacol 1990; 21:827-831.

39)       Humphreys BD, Dubyak GR Induction of the P2Z/P2X7 nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFN-g in the human THP-1monocytic cell line. J. Immunol. 157: 1996 5627 - 5637.

40)       Humphreys BD, Dubyak GR Modulation of P2X7 nucleotide receptor expression by pro- and anti- inflammatory stimuli in THP-1 monocytes. J Leukoc Biol 1998; 64:265-273.

41)       Humphreys BD Virginio, C. Surprenant A. Rice J. Dubyak GR Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues. Mol. Pharmacol. 54:1998, 22- 32.

42)       IJzerman AP, van der Wenden NM Modulators of adenosine uptake, release, and inactivation. In: Purinergic Approaches in Experimental Therapeutics Jacobson, K.A.; Jarvis, M.F., Wiley-Liss, Inc. New York, 1997, 129-148.

43)       Jacobson KA van Rhee AM. Development of selective purinoceptor agonists and antagonists. In Purinergic Approaches in Experimental Therapeutics. Eds. Jacobson KA. Jarvis M F, Wiley-Liss, New York, 1997, pp.101 - 128.

44)       Jacobson, KA, van Galen PJM, Williams M. Adenosine receptors: pharmacology, structure-activity relationships and therapeutic potential. J. Med. Chem. 1992, 35, 407 -422..

45)       Jarvis MF Psychomotor aspects of adenosine function. In: Purinergic Approaches inExperimental Therapeutics. Eds. Jacobson KA. Jarvis M F, Wiley-Liss, New York, 1997, pp.405-422.

46)       Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J , Kase H, Kuwana Y, Jenner P Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998; 43:507-513.

47)       Keil GJ, DeLander GE Spinally-mediated antinociception is induced in mice by an adenosine kinase-, but not by an adenosine deaminase-, inhibitor. Life Sci 1992; 51:L171-L176.

48)       Kennedy C, Leff P How should P2X receptors be classified pharmacologically? Trends Pharmacol. Sci. 1995, 16, 168 - 174.

49)       Kirkpatrick KA, Burnstock G Evidence that the inhibition of ATP release from sympathetic nerves by adenosine is a physiological mechanism. Gen Pharmacol 1992; 23:1045-1050.

50)       Knutsen LJS, Murray TF. Adenosine and ATP in epilepsy. In Purinergic Approaches in Experimental Therapeutics. Eds. Jacobson KA Jarvis M F. Wiley-Liss, New York, 1997, pp. 423 - 447.

51)       King BF, Townsend-Nicholson A, Burnstock G Metabotropic receptors for ATP and UTP: eploring the correspondance between native and recombinant nucleotide receptors. Trends Pharmacol. Sci. 1998; 19: 506-514.

52)       Kowaluk EA, Bhagwat SS, Jarvis MF Adenosine kinase inhibitors. Curr. Pharmaceut. Design 1998; 4: 403-416.

53)       Lammas DA. Stober C. Harvey, CJ. Kendrick N. Panchalingam S. Kumararatne DS. ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z (P2X7)receptors. Immunity, 7:1997, 433 - 444.

54)       Le KT, Babinski K, Seguela P Central P2X4 and P2X6 channel subunits coassemble into a novel heteromeric ATP receptor J Neurosci 1998; 18:7152-7159.

55)       Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor Nature 1997; 388:674-678.

56)       Lee YW, Yaksh TL Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. J Pharmacol Exp Ther 1996; 277: 1642-1648.

57)       Leff P, Robertson M, Humphries RG. The role of ADP in thrombosis and the therapeutic potential of P2T-receptor antagonists as novel antithrombotic agents. In Purinergic Approaches in Experimental Therapeutics. Eds. Jacobson KJarvis M.,Wiley-Liss, New York, 1997, pp. 203 - 216.

58)       Leung E, Walsh LK, Flippin LA, Kim EJ, Lazar DA, Seran CS, Wong EH, Eglen RM Enhancement of adenosine A1 receptor functions by benzoylthiophenes in guinea pig tissues in vitro. Naunyn Schmiedebergs Arch Pharmacol 1995; 352:206-212.

59)       Li,J Perl, ER ATP modulation of synaptic transmission in the spinal substantia gelatinosa. J. Neurosci. 15, 1995, 3357 - 3365.

60)       Linden J Allosteric enhancement of adenosine receptors. In Purinergic Approaches in Experimental Therapeutics, Jacobson KA, Jarvis MF, Wiley-Liss, New York 1997; 85-97.

61)       Linden J Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 1994; 15:298-306.

62)       Martin GE, Rossi DJ, Jarvis MF Adenosine agonists reduce conditioned avoidance responding in the rat. Pharmacol Biochem Behav 1993; 45:951 -958.

63)       Miller LP, Jelovich LA, Yao L, DaRe J, Ugarkar B, Foster AC Pre- and peristroke treatment with the adenosine kinase inhibitor, 5'- deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Neurosci Lett 1996; 220:73-76.

64)       Neary JT. Rathbone MP, Cattabeni F, Abbracchio MP Burnstock G. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci. 1996, 19, 13 - 18

65)       Nicke A, Baumert HG, Rettinger J, Eichele A, Lambrecht G, Mutschler E, Schmalzing G P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J. 1998; 17: 3016-3028.

66)       Noji, H. The rotary enzyme of the cell: the rotation of F1-ATPase Science 1998, 282, 1844 -1845.

67)       Olah ME, Stiles GL Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995; 35:581-606.

68)       Perregaux D, Gabel CA. (1994). Interleukin 1-b maturation and release in response to ATP and nigericin. J. Biol. Chem. 2669, 15195 - 15203.

69)       Poon A, Sawynok J Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain 1998; 74:235-245.

70)       Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997; 276:1265-1268.

71)       Prince DA, Stevens CF, Adenosine decreases neurotransmitter release at central synapses. Proc. Natl. Acad. Sci. U.S.A. 1992, 89: 8586 - 8590

72)       Radford KM, Virginio C, Surprenant A, North RA, Kawashima E Baculovirus expression provides direct evidence for heteromeric assembly of P2X2 and P2X3 receptors. J Neurosci 1997; 17:6529-6533.

73)       Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998 50, 413 -492.

74)       Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 1997; 272:5482-5486.

75)       Richardson PJ, Kase H, Jenner PG Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease Trends Pharmacol Sci 1997; 18:338-344.

76)       Rudolphi K, Schubert P, Parkinson FE and Fredholm BB. Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol Sci. 1992, 13, 439 - 445.

77)       Sanz JM, Chiozzi P, Di Virgilio F. Tenidap enhances P2Z/P2X7 receptor signalling in macrophages. Eur. J. Pharmacol. 355: 1998, 235 - 244,

78)       Satoh S, Matsumura H, Suzuki F, Hayasihi O. Promotion of sleep mediated by the A2a-adenosine receptor and possible involvement of this receptor in the sleep induced by prostaglandin D2 in rats. Proc Natl Acad Sci U S A. 93: 1996, 5980 - 5984.

79)       Sawynok J Adenosine receptor activation and nociception. Eur J Pharmacol 1998; 347:1-11.

80)       Searl TJ, Silinsky EM. Cross-talk between apparently independent receptors. J. Physiol. (Lond.) 1998, 513, 629.

81)       Segerdahl M, Ekblom A, Sandelin K, Wickman M, Sollevi A Perioperative adenosine infusion reduces the requirements for isoflurane and postoperative analgesics. Anesth Analg 1995; 80:1145-1149.

82)       Sollevi A Adenosine for pain control. Acta Anaesthesiol Scand Suppl 1997; 110:135-136.

83)       Sperlagh B, Vizi ES. (1996) Neuronal synthesis, storage and release of ATP. Seminar Neurosci. 8,175 - 186.

84)       Surprenant A, Rassendren F, Kawashima E, North RA, Buell G The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996; 272:735-738.

85)       Thorne PR, Housley GD Purinergic signalling in sensory systems. (1996). Seminar Neurosci. 8, 233-246.

86)       Thornberry NA, Lazebnik Y Caspases: enemies within. Science 1998; 281: 1312-1316.

87)       Tordorov LD, Mihaylova-Todorova S, Westfall TD, Sneddon P, Kennedy C, Bjur RA, Westfall DP. Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation. Nature 1997, 387, 76 - 79.

88)       Torres GE, Haines WR, Egan TM, Voigt MM Co-expression of P2X1 and P2X5 Receptor subunits reveals a novel ATP-gated ion channel. Mol. Pharmacol. 1998; 54: 989-993.

89)       Virginio C, Robertson G, Surprenant A, North RA Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol 1998; 53:969 -973.

90)       Vulchanova L, Arvidsson U, Riedl M, Wang J, Buell G, Surprenant A, North RA, Elde R. Differential distribution of two ATP-gated ion channels (P2X receptors) determined by immunocytochemistry. Proc. Natl. Acad. Sci. U. S. A. 93, 1996, 8063 - 8067.

91)       Williams, M, Burnstock, G Purinergic Neurotransmission and Neuromodulation: A Historical Perspective. In: Jacobson, KA, Jarvis, MF, eds. Purinergic Approaches to Experimental Therapeutics. New York: Wiley-Liss, 1997; 3-26.

92)       Winn HR, Rubio R, Berne RM Brain adenosine concentration during hypoxia in rats. Am J Physiol 1981; 241:H235-H242.

93)       Woolf, C.J. The dorsal horn: state dependent sensory processing and the generation of pain. In Textbook of Pain, 3rd Ed. Wall, P., Melzack, R.D. Eds, Churchill Livingstone, Edinburgh, 1994, 101-112

94)       Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu, T A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387, 620 - 624.

95)       Yoon KW, Rothman SM. Adenosine inhibits excitatory but not inhibitory synaptic transmission in the hippocampus. J. Neurosci. 1991, 11: 1375 - 1380.

96)       Zetterstrom T, Vernet L, Ungerstedt U, Tossman U, Jonzon B, Fredholm BB. Purine levels in the intact rat brain. Studies with an implanted perfused hollow fibre. Neurosci. Lett. 1982, 29, 111 - 115.

97)       Zhang G, Franklin PH, Murray TF Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J Pharmacol Exp Ther 1993; 264:1415-1424.

98)       Zhou JG, Meno JR, Hsu SS, Winn HR Effects of theophylline and cyclohexyladenosine on brain injury following normo- and hyperglycemic ischemia: a histopathologic study in the rat. J Cereb Blood Flow Metab 1994; 14:166-173.

99)       Zimmerman H.Extracellular purine metabolism. Drug Dev. Res. 1996, 39, 337 - 352.

Return to Chapter

published 2000